Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Mar 19;3(3):CD009031.
doi: 10.1002/14651858.CD009031.pub2.

Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event

Rodolfo Rivas-Ruiz  1 , Miguel Villasis-Keever, Guadalupe Miranda-Novales, Osvaldo D Castelán-Martínez, Silvia Rivas-Contreras
Affiliations
Meta-Analysis

Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event

Rodolfo Rivas-Ruiz et al. Cochrane Database Syst Rev. .

Abstract

Background: People with febrile neutropaenia are usually treated in a hospital setting. Recently, treatment with oral antibiotics has been proven to be as effective as intravenous therapy. However, the efficacy and safety of outpatient treatment have not been fully evaluated.

Objectives: To compare the efficacy (treatment failure and mortality) and safety (adverse events of antimicrobials) of outpatient treatment compared with inpatient treatment in people with cancer who have low-risk febrile neutropaenia.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 11) in the Cochrane Library, MEDLINE via Ovid (from 1948 to November week 4, 2018), Embase via Ovid (from 1980 to 2018, week 48) and trial registries (National Cancer Institute, MetaRegister of Controlled Trials, Medical Research Council Clinical Trial Directory). We handsearched all references of included studies and major reviews.

Selection criteria: Randomised controlled trials (RCTs) comparing outpatient with inpatient treatment for people with cancer who develop febrile neutropaenia. The outpatient group included those who started treatment as an inpatient and completed the antibiotic course at home (sequential) as well as those who started treatment at home.

Data collection and analysis: Two review authors independently assessed trial eligibility, methodological quality, and extracted data. Primary outcome measures were: treatment failure and mortality; secondary outcome measures considered were: duration of fever, adverse drug reactions to antimicrobial treatment, duration of neutropaenia, duration of hospitalisation, duration of antimicrobial treatment, and quality of life (QoL). We estimated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous data; we calculated weighted mean differences for continuous data. Random-effects meta-analyses and sensitivity analyses were conducted.

Main results: We included ten RCTs, six in adults (628 participants) and four in children (366 participants). We found no clear evidence of a difference in treatment failure between the outpatient and inpatient groups, either in adults (RR 1.23, 95% CI 0.82 to 1.85, I2 0%; six studies; moderate-certainty evidence) or children (RR 1.04, 95% CI 0.55 to 1.99, I2 0%; four studies; moderate-certainty evidence). For mortality, we also found no clear evidence of a difference either in studies in adults (RR 1.04, 95% CI 0.29 to 3.71; six studies; 628 participants; moderate-certainty evidence) or in children (RR 0.63, 95% CI 0.15 to 2.70; three studies; 329 participants; moderate-certainty evidence).According to the type of intervention (early discharge or exclusively outpatient), meta-analysis of treatment failure in four RCTs in adults with early discharge (RR 1.48, 95% CI 0.74 to 2.95; P = 0.26, I2 0%; 364 participants; moderate-certainty evidence) was similar to the results of the exclusively outpatient meta-analysis (RR 1.15, 95% CI 0.62 to 2.13; P = 0.65, I2 19%; two studies; 264 participants; moderate-certainty evidence).Regarding the secondary outcome measures, we found no clear evidence of a difference between outpatient and inpatient groups in duration of fever (adults: mean difference (MD) 0.2, 95% CI -0.36 to 0.76, 1 study, 169 participants; low-certainty evidence) (children: MD -0.6, 95% CI -0.84 to 0.71, 3 studies, 305 participants; low-certainty evidence) and in duration of neutropaenia (adults: MD 0.1, 95% CI -0.59 to 0.79, 1 study, 169 participants; low-certainty evidence) (children: MD -0.65, 95% CI -0.1.86 to 0.55, 2 studies, 268 participants; moderate-certainty evidence). With regard to adverse drug reactions, although there was greater frequency in the outpatient group, we found no clear evidence of a difference when compared to the inpatient group, either in adult participants (RR 8.39, 95% CI 0.38 to 187.15; three studies; 375 participants; low-certainty evidence) or children (RR 1.90, 95% CI 0.61 to 5.98; two studies; 156 participants; low-certainty evidence).Four studies compared the hospitalisation time and found that the mean number of days of hospital stay was lower in the outpatient treated group by 1.64 days in adults (MD -1.64, 95% CI -2.22 to -1.06; 3 studies, 251 participants; low-certainty evidence) and by 3.9 days in children (MD -3.90, 95% CI -5.37 to -2.43; 1 study, 119 participants; low-certainty evidence). In the 3 RCTs of children in which days of antimicrobial treatment were analysed, we found no difference between outpatient and inpatient groups (MD -0.07, 95% CI -1.26 to 1.12; 305 participants; low-certainty evidence).We identified two studies that measured QoL: one in adults and one in children. QoL was slightly better in the outpatient group than in the inpatient group in both studies, but there was no consistency in the domains included.

Authors' conclusions: Outpatient treatment for low-risk febrile neutropaenia in people with cancer probably makes little or no difference to treatment failure and mortality compared with the standard hospital (inpatient) treatment and may reduce time that patients need to be treated in hospital.

PubMed Disclaimer

Conflict of interest statement

RRR: Has worked for Abbott as speaker and consultant in Biostatistics, and works full time for Instituto Mexicano del Seguro Social, which is a government institution. MVK: none known MGMN: none known DOCM: none known SRC: none known

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.1 Treatment failure.
5
5
Forest plot of comparison: 1 Outpatients versus inpatients ‐ adults, outcome: 1.2 Mortality.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ahmed 2007 {published data only}
    1. Ahmed N, El‐Mahallawy HA, Ahmed IA, Nassif S, El‐Beshlawy A, El‐Haddad A. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study. Pediatric Blood & Cancer 2007;49(6):786‐92. - PubMed
Brack 2012 {published data only}
    1. Brack E, Bodner N, Simon A, Liebundgut K, Kühne T, Niggli FK, et al. First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatric Blood & Cancer 2012;59(3):423‐30. - PubMed
Hidalgo 1999 {published data only}
    1. Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. A prospective, randomized clinical trial. Cancer 1999;85(1):213‐9. - PubMed
Innes 2003 {published data only}
    1. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in‐patient intravenous antibiotics for low‐risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. British Journal of Cancer 2003;89(1):43‐9. - PMC - PubMed
López‐Hernández 2010 {published data only}
    1. López‐Hernández MA, Herrera‐Álvarez W, Sibaja‐Nieto L, Álvarez‐Vera JL. Low‐risk febrile neutropenia in patients with acute lymphoblastic leukemia. Amikacin‐ceftriaxone or oral fluoroquinolones [Neutropenia febril de bajo riesgo en pacientes con leucemia aguda linfoblástica. Amikacina‐ceftriaxona o fluoroquinolonas orales.]. Medicina Interna de México 2010;26(3):219‐25.
Malik 1995 {published data only}
    1. Malik IA, Khan WA, Karim M, Aziz A. Feasibility of outpatient management of fever in cancer patients with low‐risk neutropenia: results of prospective randomized trial. American Journal of Medicine 1995;98(3):224‐31. - PubMed
Orme 2014 {published data only}
    1. Orme LM, Babl FE, Barnes C, Barnett P, Donath S, Ashley DM. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomized trial. Pediatric Blood & Cancer 2014;61(8):1427‐33. - PubMed
Rapoport 1999 {published data only}
    1. Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard In‐patient care. Chemotherapy 1999;45(6):466‐76. - PubMed
Santolaya 2004 {published data only}
    1. Santolaya ME, Álvarez AM, Avilés CL, Becker A, Cofré J, Cumsille MA, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Journal of Clinical Oncology 2004;22(18):3784‐9. - PubMed
Talcott 2011 {published data only}
    1. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. Journal of Clinical Oncology 2011;29(30):3984‐9. - PMC - PubMed
    1. Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, et al. Safety of early discharge for low‐risk patients with febrile neutropenia: a multicenter randomized controlled trial. Journal of Clinical Oncology 2011;29(30):3977‐83. - PMC - PubMed

References to studies excluded from this review

Gupta 2009 {published data only}
    1. Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin‐clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low‐risk febrile neutropenia. Journal of Pediatric Hematology/Oncology 2009;31(9):635‐41. - PubMed
Kern 2013 {published data only}
    1. Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, et al. Oral antibiotics for fever in low‐risk neutropenic patients with cancer: a double‐blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy ‐ EORTC infectious diseases group trial XV. Journal of Clinical Oncology 2013;31(9):1149‐56. - PubMed
Klaassen 2000 {published data only}
    1. Klaassen RJ, Goodman R, Pham BA, Doyle JJ. "Low‐risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. Journal of Clinical Oncology 2000;18(5):1012‐9. - PubMed
Minotti 1999 {published data only}
    1. Minotti V, Gentile G, Bucaneve G, Iori AP, Micozzi A, Cavicchi F, et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Supportive Care in Cancer 1999;7(3):134‐9. - PubMed
Mullen 1999 {published data only}
    1. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86(1):126‐34. - PubMed
Paganini 2001 {published data only}
    1. Paganini H, Rodriguez‐Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001;91(8):1563‐7. - PubMed
Paganini 2003 {published data only}
    1. Paganini H, Gómez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, et al. Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single‐center, randomized, controlled trial in Argentina. Cancer 2003;97(7):1775‐80. - PubMed
Petrilli 2000 {published data only}
    1. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low‐risk pediatric oncology patients: randomized prospective trial. Medical and Pediatric Oncology 2000;34(2):87‐91. - PubMed
Rubenstein 1993 {published data only}
    1. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer. Cancer 1993;71(11):3640‐6. - PubMed

Additional references

Alexander 2002
    1. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. Journal of Pediatric Hematology/Oncology 2002;24(1):38‐42. - PubMed
Ammann 2003
    1. Ammann RA, Hirt A, Lüthy AR, Aebi C. Identification of children presenting with fever in chemotherapy‐induced neutropenia at low risk for severe bacterial infection. Medical and Pediatric Oncology 2003;41(5):436‐43. - PubMed
Bodey 1966
    1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64(2):328‐40. - PubMed
Buchanan 1993
    1. Buchanan GR. Approach to treatment of the febrile cancer patient with low‐risk neutropenia. Hematology/Oncology Clinics of North America 1993;7(5):919‐35. - PubMed
Carstensen 2008
    1. Carstensen M, Sorensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. Journal of Supportive Oncology 2008;6(5):199‐208. - PubMed
Chamilos 2005
    1. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, et al. Outpatient treatment of low‐risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005;103(12):2629‐35. - PubMed
Cherif 2004
    1. Cherif H, Bjorkholm M, Engervall P, Johansson P, Ljungman P, Hast R, et al. A prospective, randomized study comparing cefepime and imipenem‐cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scandinavian Journal of Infectious Diseases 2004;36(8):593‐600. - PubMed
Cherif 2006
    1. Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 2006;91(2):215‐22. - PubMed
Close 1995
    1. Close P, Burkey F, Kasak A, Danz P, Lange B. A prospective, controlled evaluation of home chemotherapy for children with cancer. Pediatrics 1995;95(6):896‐900. - PubMed
Consensus panel 1990
    1. Consensus panel, Immunocompromised Host Society. The design, analysis,and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases 1990;161(3):397‐401. - PubMed
Deeks 2001
    1. Deeks JJ, Altman DJ, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
Delebarre 2014
    1. Delebarre M, Macher E, Mazingue F, Martinot A, Dubos F. Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis.. Pediatric Blood & Cancer 2014;61(10):1786‐91. - PubMed
Elting 1997
    1. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcome of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clinical Infectious Diseases 1997;25(2):247‐59. - PubMed
Elting 2008
    1. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. Journal of Clinical Oncology 2008;26(4):606‐11. - PubMed
Feld 1998
    1. Feld R. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?. Supportive Care in Cancer 1998;6(5):444‐8. - PubMed
Feld 2002
    1. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KV, et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clinical of Infectious Diseases 2002;35(12):1463‐8. - PubMed
Freifeld 1999
    1. Freifeld A, Marchigiani D, Walsh T. A double‐blind comparison of empirical oral and intravenous antibiotic therapy for low‐risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine 1999;341(5):305‐11. - PubMed
Heinz 2017
    1. Heinz WJ, Buchheidt D, Christopeit M, Lilienfeld‐Toal M, Cornely OA, Einsele H, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology 2017;11:1775‐92. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thomson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. British Medical Journal 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org/.
Hughes 1997
    1. Hughes WT, Armstrong D, Bodey GP, Brown A, Edwards J, Feld R, et al. Infectious Diseases Society of America. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases 1997;25(3):551‐73. - PubMed
Hughes 2002
    1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002;34:730‐51. - PubMed
IDSA 2010
    1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update. Clinical Infectious Diseases 2011;52(4):427‐31. - PubMed
IDSA 2018
    1. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline update. Journal of Clinical Oncology 2018;36(14):1443‐53. - PubMed
Kamana 2005
    1. Kamana M, Escalante C, Mullen CA, Frisbee‐Hume S, Rolston K. Bacterial infections in low‐risk febrile neutropenic patients. Cancer 2005;104(2):422‐26. - PubMed
Karthaus 1998
    1. Karthaus M, Egerer G, Kullmann KH, Ritter J, Jürgens H. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. European Journal of Clinical Microbiology & Infectious Diseases 1998;17(7):501‐4. - PubMed
Kern 1999
    1. Kern WV, Cometta A, Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New England Journal of Medicine 1999;341(5):312‐18. - PubMed
Klaassen 2000a
    1. Klaassen RJ, Allen U, Doyle J. Randomized placebo‐controlled trial of oral antibiotics in pediatric oncology patients at low risk with fever and neutropenia. Journal of Pediatric Hematology/Oncology 2000;22(5):405‐11. - PubMed
Klastersky 2000
    1. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low‐risk febrile neutropenic cancer patients . Journal of Clinical Oncology 2000;18(16):3038‐51. - PubMed
Klastersky 2006
    1. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of Clinical Oncology 2006;24(25):4129‐34. - PubMed
Klastersky 2013
    1. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low‐risk febrile neutropenic cancer patients. Supportive Care in Cancer 2013;21(5):1487‐95. - PubMed
Klastersky 2016
    1. Klastersky J, Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology 2016;25(Suppl 5):v111‐8. - PubMed
Lehrnbecher 2017
    1. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem‐cell transplantation recipients: 2017 update. Journal of Clinical Oncology 2017;35(18):2082‐94. - PubMed
Loeffen 2016
    1. Loeffen EA, Poele EM, Tissing WJ, Boezen HM, Bont ES. Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD008382.pub2] - DOI - PMC - PubMed
Mesters 2000
    1. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernández JA, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Critical Care Medicine 2000;28(7):2209‐16. - PubMed
Mullen 1990
    1. Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low‐risk patient. Journal of Clinical Oncology 1990;8(12):998‐1004. - PubMed
Mustafa 1996
    1. Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Journal of Pediatrics 1996;128(6):847‐9. - PubMed
Nijhuis 2005
    1. Nijhuis CO, Kamps WA, Daenen SM, Gietema JA, Graaf WT, Groen HJ, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. Journal of Clinical Oncology 2005;23(30):7437‐44. - PubMed
Orudjev 2002
    1. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Medical and Pediatric Oncology 2002;39(2):77‐85. - PubMed
Quezada 2007
    1. Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA. Medical and non‐medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatric Blood & Cancer 2007;48(3):273‐7. - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Santolaya 2002
    1. Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Enriquez N, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clinical Infectious Diseases 2002;35(6):678‐83. - PubMed
Santolaya 2010
    1. Santolaya ME. Supportive care in children. Current Opinion in Oncology 2010;22(4):323‐9. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sebban 2008
    1. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low‐risk neutropenic fever in cancer patients suitable for early hospital discharge. Supportive Care in Cancer 2008;16(9):1017‐23. - PubMed
Soker 2001
    1. Soker M, Colpan L, Ece A, Deveciolu C, Haspolat K. Serum levels of IL‐1 beta, sIL‐2R, IL‐6, IL‐8, and TNF‐alpha in febrile children with cancer and neutropenia. Medical Oncology 2001;18(1):51‐7. - PubMed
Sung 2004
    1. Sung L, Feldman BM, Schwamborn G, Paczesny D, Cochrane A, Greenberg ML, et al. Inpatient versus outpatient management of low‐risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. Journal of Clinical Oncology 2004;22(19):3922‐9. - PubMed
Talcott 1988
    1. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low‐risk subgroup at presentation. Archives of Internal Medicine 1988;148(12):2561‐8. - PubMed
Talcott 1992
    1. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two‐center validation of a prediction rule. Journal of Clinical Oncology 1992;10(2):316‐22. - PubMed
Teuffel 2011
    1. Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta‐analysis. Annals of Oncology 2011;22(11):2358‐65. - PubMed
Vidal 2013
    1. Vidal L, Paul M, Ben‐Dor I, Pokroy E, Soares‐Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD003992.pub3] - DOI - PubMed

References to other published versions of this review

Rivas‐Ruiz 2011
    1. Rivas‐Ruiz R, Villasis‐Keever M, Miranda‐Novales MG. Outpatient treatment for patients with cancer who develop a low‐risk febrile neutropenic event. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD009031] - DOI - PMC - PubMed

MeSH terms

Substances